Gene therapy for the haemophilias

Haemophilia

Volumn 6, Issue SUPPL. 1, 2000, Pages 115-119

  Thompson, A R ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WORLD FEDERATION OF HEMOPHILIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; COMPLEMENTARY DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELL CULTURE; GENE THERAPY; GENE TRANSFER; HEMOPHILIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY;

CLINICAL TRIALS; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA A; HUMANS;

EID: 0033911047     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2000.00055.x     Document Type: Short Survey

References (20)

1. Brownlee GG. Prospects for gene therapy of haemophilia A and B. Br Med Bull, 1995; 51: 91-105.
2. Chuah MK, Collen D, VandenDriessche T. Gene therapy for hemophilia: hopes and hurdles. Crit Rev Oncol Hematol, 1998; 28: 153-71.
3. Connelly S, Kaleko M. Gene therapy for hemophilia A. Thromb Haemost, 1997; 78: 31-6.
4. Eisensmith RC, Woo SL. Viral vector-mediated gene therapy for hemophilia B. Thromb Haemost, 1997; 78: 24-30.
5. Herzog RW, High KA. Problems and prospects in gene therapy for hemophilia. Curr Opin Hematol, 1998; 5: 321-6.
6. Kurachi K, Yao SN. Gene therapy of hemophilia B. Thromb Haemost, 1993; 70: 193-7.
7. Miller AD. Putting muscle to work for gene therapy. Nat Med, 1997; 3: 278-9.
8. Thompson AR. Progress towards gene therapy for the hemophilias. Thromb Haemost, 1995; 74: 45-51.
9. Verma IM. Gene therapy. Sci Am, 1990; 263(68-72): 81-4.
10. Schnieke AE, Kind AJ, Ritchie WA et al. Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. Science, 1997; 278: 2130-3.
11. Kren BT, Bandyopadhyay P, Steer CJ. In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides. Nature Med, 1998; 4: 285-90.
12. Greengard JS, Bodner M, McCormack J et al. Intravenous retroviral vectors expressing human factor VIII results in longterm expression in rabbits of various age groups. Blood, 1998; 92(Suppl. 1): 296a(Abstract).
13. Kessler CM, Spira J, Magill M. Safety and efficacy of a second generation, B-domain deleted recombinant factor VIII (r-VIII SQ) in previously treated patients (PTPs). A four year update. Blood, 1998; 92(Suppl. 1): 555a(Abstract).
14. Lusher JM, Spira J, Magill M. A four-year update of safety and efficacy of a second generation B-domain deleted factor VIII (R-VIII SQ) in previously untreated hemophilia A patients. Blood, 1998; 92(Suppl. 1): 555a(Abstract).
15. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet, 1997; 17: 314-7.
16. Connelly S, Andrews JL, Gallo AM et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood, 1998; 91: 3273-81.
17. Alemany R, Dai Y, Lou YC et al. Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations. J Virol Methods, 1997; 68: 147-59.
18. Snyder RO, Miao CH, Meuse L et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med, 1999; 5: 64-70.
19. Herzog RW, Yang EY, Couto LB et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med, 1999; 5: 56-63.
20. Gnatenko D, Hearing P, Jesty J, Bahou W. An adenoassociated/adenovirus hybrid vector generates high-level human factor VIII in vitro. Blood, 1998; 92(Suppl. 1): 146a.